Skip to main content
Caplight Logo









Belharra Therapeutics

Belharra Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://belharratx.com/

Last Round

Series A

Jan 4, 2023

Total Funding Raised

$50M

Company Overview

Belharra Therapeutics is a biotechnology company that develops a photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously undruggable protein targets.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

chemoproteomicssmall molecule discoveryundruggable targetsdrug discovery platformproteomicsbiotech R&Dsmall molecule therapeuticstherapeutic discoverytarget identificationAI drug discoverybiotech partnershippharma collaborationdrug discovery pipelinein silico drug designcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Belharra Therapeutics Comparables

Compare Belharra Therapeutics with similar companies based on industry and business-model similarity.

Belharra Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BridGene Biosciences
89%
Nexo Therapeutics
83%
Frontier Medicines
82%

Belharra Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 4, 2023

Belharra Therapeutics Investors

Notable investors and investment history

Belharra Therapeutics investors
InvestorRounds
Versant VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 10, 2025

    Sean Buchanan appointed as Chief Scientific Officer.

  • Jan 4, 2023

    $50M round led by Versant Ventures

Belharra Therapeutics Filings

Explore SEC and related filing metadata, where available.

Belharra Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Belharra Therapeutics's valuation, stock price, and market status.

Is Belharra a public or private company?

Belharra is a private company.

What is the current stock price of Belharra?

Belharra is a private company with no public stock price. No recent secondary market data is available.

How much is Belharra worth (valuation)?

Valuation information for Belharra is not publicly available.

Can I buy Belharra stock?

Belharra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Belharra's last funding round?

Belharra's most recent funding round was Series A on January 4, 2023.

Who are the main investors in Belharra?

Key investors in Belharra include Versant Ventures.

Will Belharra IPO soon?

No public IPO plans have been announced for Belharra.

How can I track Belharra secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Belharra's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range34
Year Founded2021
Last FundingJan 4, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?